MD Anderson Cancer Center expert, Dr. Michael Keating, and Dr. Januario Castro, of UC San Diego Moores Cancer Center, discuss how CLL Treatments have evolved over time. They explore the introduction of fludarabine and achieving complete remission in patients for the first time. The experts go on to discuss the impact of FCR (fludarabine, cyclophosphamide, and rituximab) on CLL treatment and how it affects the future for CLL patients. Dr. Castro and Dr. Keating also address the role of new oral therapies and transplant for CLL treatment.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…